Toku Eyes | Window to your future health | Auckland, New …
WEBToku develops tools using AI and retinal photography to enable accessible healthcare for early and accurate diagnosis of health conditions. Our AI Platforms BioAge
CLAiR - Toku
WEBLow cost, non invasive, immediate & accessible. CLAiR gives an immediate result. It is typically lower cost than CVD risk calculations requiring biomarker and blood testing. It is non invasive and involves no radiation. Notes: CLAiR has CE and UKCA marks and is cleared for sale in some regions.
Toku Eyes - LinkedIn
WEBToku’s AI platform utilizes a revolutionary, patented method to evaluate more than 23 million technical parameters and 12 biological parameters in each retinal image, to produce a BioAge...
Toku: a clear vision for preventive healthcare - University of …
WEBFeb 20, 2024 · Utilising advanced AI technology, Toku's CLAiR platform scans the eye to predict not only blindness but also the likelihood of other cardiovascular diseases and events like strokes and heart attacks. It is currently used in …
FDA Grants Breakthrough Device Status to Toku’s ... - Business Wire
WEBNov 2, 2023 · Toku’s AI (CLAiR) technology platform has received FDA Breakthrough Device status, and if cleared by the FDA will deliver real-time cardiovascular disease (CVD) risk assessments through routine...
A coming-of-BioAge story - NZ Optics
WEBNov 13, 2023 · Unveiled at O=Mega23, Toku Eyes’ new artificial intelligence (AI)-based software reveals patients’ ‘BioAge’, based on their cardiovascular health via a retinal scan.
Our Research | Toku Eyes - Window to your future health - Europe
WEBToku develops tools using AI and retinal photography to enable accessible healthcare for early and accurate diagnosis of health conditions. Our AI Platforms BioAge
Toku Eyes - Products, Competitors, Financials, Employees, …
WEBToku Eyes focuses on preventative healthcare through the use of retinal image analysis in the medical diagnostics industry. The company offers non-invasive tools for assessing cardiovascular disease risk and determining biological age to facilitate early diagnosis and management of health conditions.
Toku Eyes on LinkedIn: Introducing BioAge | America's Best
WEBNational Vision is the first retailer in the U.S. to offer BioAge, a product by Toku Eyes that utilizes retinal images to determine a person’s biological age, which can give an indication of ...
Device Makes Eyes the Window to the Kidneys
WEBMay 16, 2024 · Toku’s MyKidneyAI, a screening technology that uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease risk in people with diabetes, was last month granted Breakthrough Device designation for it by the U.S. Food and Drug Administration.
- Some results have been removed